About Nu Skin Enterprises (NYSE:NUS)
Nu Skin Enterprises, Inc. is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system. The Pharmanex product line includes ageLOC Youth nutritional supplement, ageLOC TR90 weight management and body shaping system, and LifePak nutritional supplements. The Company has operations in various geographic regions, including Greater China, North Asia, Americas, South Asia/Pacific, and Europe, the Middle East and Africa (EMEA). It is focused on offering ageLOC Youth nutritional supplement and ageLOC Me personalized skin care system. The Company also offers household products and technology services.
Industry, Sector and Symbol:
- Sector: Consumer Staples
- Industry: Personal Products
- Sub-Industry: Personal Products
- Symbol: NYSE:NUS
- CUSIP: 67018T10
- Web: www.nuskinenterprises.com
- Market Cap: $3.37346 billion
- Outstanding Shares: 52,942,000
- 50 Day Moving Avg: $62.20
- 200 Day Moving Avg: $59.60
- 52 Week Range: $46.35 - $65.85
Sales & Book Value:
- Trailing P/E Ratio: 21.12
- Foreward P/E Ratio: 18.47
- P/E Growth: 2.32
- Annual Revenue: $2.18 billion
- Price / Sales: 1.53
- Book Value: $13.20 per share
- Price / Book: 4.78
- Annual Dividend: $1.44
- Dividend Yield: 2.3%
- EBITDA: $326.95 million
- Net Margins: 7.53%
- Return on Equity: 24.14%
- Return on Assets: 11.26%
- Debt-to-Equity Ratio: 0.46%
- Current Ratio: 1.80%
- Quick Ratio: 1.18%
- Average Volume: 613,931 shs.
- Beta: 1.4
- Short Ratio: 10.12
Frequently Asked Questions for Nu Skin Enterprises (NYSE:NUS)
What is Nu Skin Enterprises' stock symbol?
Nu Skin Enterprises trades on the New York Stock Exchange (NYSE) under the ticker symbol "NUS."
How often does Nu Skin Enterprises pay dividends? What is the dividend yield for Nu Skin Enterprises?
Nu Skin Enterprises declared a quarterly dividend on Thursday, August 3rd. Shareholders of record on Friday, August 25th will be given a dividend of $0.36 per share on Wednesday, September 13th. This represents a $1.44 dividend on an annualized basis and a yield of 2.28%. The ex-dividend date is Wednesday, August 23rd. View Nu Skin Enterprises' Dividend History.
How were Nu Skin Enterprises' earnings last quarter?
Nu Skin Enterprises, Inc. (NYSE:NUS) announced its earnings results on Wednesday, August, 2nd. The company reported $0.77 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.69 by $0.08. The firm had revenue of $550.10 million for the quarter, compared to analyst estimates of $548.09 million. Nu Skin Enterprises had a net margin of 7.53% and a return on equity of 24.14%. The firm's revenue for the quarter was down 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.79 EPS. View Nu Skin Enterprises' Earnings History.
When will Nu Skin Enterprises make its next earnings announcement?
What guidance has Nu Skin Enterprises issued on next quarter's earnings?
Nu Skin Enterprises issued an update on its third quarter earnings guidance on Thursday, October, 12th. The company provided EPS guidance of $0.74-0.76 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.77. The company issued revenue guidance of $559-563 million, compared to the consensus revenue estimate of $559.04 million.
Where is Nu Skin Enterprises' stock going? Where will Nu Skin Enterprises' stock price be in 2017?
6 analysts have issued 12 month target prices for Nu Skin Enterprises' shares. Their forecasts range from $50.00 to $80.00. On average, they anticipate Nu Skin Enterprises' share price to reach $60.67 in the next twelve months. View Analyst Ratings for Nu Skin Enterprises.
What are analysts saying about Nu Skin Enterprises stock?
Here are some recent quotes from research analysts about Nu Skin Enterprises stock:
- 1. According to Zacks Investment Research, "Nu Skin is a premier anti-aging company. The company's anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system. " (10/17/2017)
- 2. Pivotal Research analysts commented, "We think that weighed on the shares after hours but the company did a fine job of explaining the sharp shift in EPS and sales to the 4Q. In the 4Q17, they expect LTO sales of $100 million, with none in the 2Q or 3Q. Last year there were $106 million of LTO sales in the 2Q and $56 million in the 3Q so that is the tough comp we face this year in the 2Q and 3Q, and the easy comp in 4Q. The company shrunk its share base by 4.2% Y/Y, more aggressive than the normal 2%-3% share shrink. Yet, only acquired $7 million of shares in the 1Q. New CFO Mark Lawrence affirmed his support of the company’s capital allocation policy. At quarter end the company had only $81 million of net debt." (5/4/2017)
- 3. Jefferies Group LLC analysts commented, "Last night, NUS reported 4Q results. Despite an early December update, 4Q revenue still missed the low end of guidance by ~$19m (-3.4%), well below street estimates (-5.2%, -$29m). An unexpected +$0.10 tax add-back helped EPS reach the guidance midpoint (in-line with consensus). 1Q revenue/EPS -2.6% and -11% below the street (midpoint) may weigh on the stock, but reaffirming FY guidance suggests an optimistic outlook for LumiSpa in 4Q' 1Q guidance below the street may weigh on shares near-term. Although management reaffirmed its FY guidance, 1Q revenue of $480-500m (implied 3-8% CC growth) is just below the street at the high end (consensus $503m), and -2.6% below at the midpoint. EPS guidance of $0.47-0.51 is -$0.06 (-11%) below consensus at the midpoint. This weak 1Q guidance, combined with the 4Q revenue miss, may weigh on the shares nearterm. However with FY guidance re-affirmed, easing comps in 2H, and an expected launch of LumiSpa in October, the back half of 2017 sets up for accelerating revenue growth, which could prove to be an upside catalyst for the stock." (2/17/2017)
Who are some of Nu Skin Enterprises' key competitors?
Some companies that are related to Nu Skin Enterprises include Energizer Holdings (EPC), Matthews International Corporation (MATW), USANA Health Sciences (USNA), PZ Cussons plc (PZC), Revlon (REV), Avon Products (AVP), Nautilus Group, Inc. (The) (NLS), KP Tissue (KPT), Swallowfield plc (SWL), Blackmores Limited (BKL), DS Healthcare Group (DSKX), L'Oreal SA (OR) and Litebulb Group Ltd (LBB).
Who are Nu Skin Enterprises' key executives?
Nu Skin Enterprises' management team includes the folowing people:
- Steven J. Lund, Executive Chairman of the Board
- Ryan S. Napierski, President
- Ritch N. Wood, Chief Executive Officer
- Mark H. Lawrence, Chief Financial Officer
- Joseph Y. Chang Ph.D., Executive Vice President - Product Development, Chief Scientific Officer
- D. Matthew Dorny, General Counsel, Secretary
- Daniel W. Campbell, Lead Independent Director
- Nevin N. Andersen, Independent Director
- Andrew D. Lipman, Independent Director
- Neil H. Offen, Independent Director
Who owns Nu Skin Enterprises stock?
Nu Skin Enterprises' stock is owned by a variety of of institutional and retail investors. Top institutional investors include APG Asset Management N.V. (0.29%), Shell Asset Management Co. (0.07%), State Treasurer State of Michigan (0.04%), Meeder Asset Management Inc. (0.02%) and Balasa Dinverno & Foltz LLC (0.01%). Company insiders that own Nu Skin Enterprises stock include Andrew D Lipman, D Matthew Dorny, Daniel W Campbell, Joseph Y Chang, Ritch N Wood, Ryan S Napierski and Steven Lund. View Institutional Ownership Trends for Nu Skin Enterprises.
Who sold Nu Skin Enterprises stock? Who is selling Nu Skin Enterprises stock?
Nu Skin Enterprises' stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan. Company insiders that have sold Nu Skin Enterprises stock in the last year include D Matthew Dorny, Daniel W Campbell, Ryan S Napierski and Steven Lund. View Insider Buying and Selling for Nu Skin Enterprises.
Who bought Nu Skin Enterprises stock? Who is buying Nu Skin Enterprises stock?
Nu Skin Enterprises' stock was purchased by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Shell Asset Management Co., Balasa Dinverno & Foltz LLC and Meeder Asset Management Inc.. View Insider Buying and Selling for Nu Skin Enterprises.
How do I buy Nu Skin Enterprises stock?
Shares of Nu Skin Enterprises can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nu Skin Enterprises' stock price today?
MarketBeat Community Rating for Nu Skin Enterprises (NYSE NUS)MarketBeat's community ratings are surveys of what our community members think about Nu Skin Enterprises and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Nu Skin Enterprises stock can currently be purchased for approximately $63.16.
Consensus Ratings for Nu Skin Enterprises (NYSE:NUS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Sell Ratings, 2 Hold Ratings, 2 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||$60.67 (3.95% downside)|Consensus Price Target History for Nu Skin Enterprises (NYSE:NUS)
Analysts' Ratings History for Nu Skin Enterprises (NYSE:NUS)
(Data available from 10/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/3/2017||Stifel Nicolaus||Set Price Target||Sell||$50.00||High|
|7/10/2017||Bank of America Corporation||Boost Price Target||Underperform||$53.00 -> $57.00||Low|
|6/22/2017||Pivotal Research||Reiterated Rating||Buy||$65.00 -> $80.00||High|
|6/21/2017||Deutsche Bank AG||Boost Price Target||Buy||$63.00 -> $66.00||Low|
|4/26/2017||Sidoti||Downgrade||Buy -> Neutral||$59.00||Medium|
|2/17/2017||Jefferies Group LLC||Set Price Target||Hold -> Hold||$55.00 -> $52.00||N/A|
|9/21/2016||Citigroup Inc.||Boost Price Target||Buy||$66.00 -> $69.00||N/A|
|12/8/2015||Canaccord Genuity||Reiterated Rating||Hold||$40.00||N/A|
|11/7/2015||J P Morgan Chase & Co||Reiterated Rating||Hold||$40.00||N/A|
Earnings History for Nu Skin Enterprises (NYSE:NUS)Earnings History by Quarter for Nu Skin Enterprises (NYSE NUS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||Q2 2017||$0.69||$0.77||$548.09 million||$550.10 million||View||Listen|
|5/3/2017||Q1 2017||$0.50||$0.51||$493.65 million||$499.10 million||View||Listen|
|2/16/2017||Q416||$0.80||$0.79||$553.83 million||$531.30 million||View||Listen|
|11/3/2016||Q316||$0.84||$0.98||$583.74 million||$604.00 million||View||Listen|
|8/4/2016||Q216||$0.79||$0.79||$578.87 million||$600.05 million||View||Listen|
|4/28/2016||Q116||$0.37||$0.42||$465.08 million||$471.80 million||View||Listen|
|2/11/2016||Q415||$0.73||$0.62||$585.92 million||$572.20 million||View||Listen|
|10/29/2015||Q315||$0.84||$0.84||$571.43 million||$571.30 million||View||Listen|
|8/6/2015||Q215||$0.72||$0.75||$552.11 million||$560.20 million||View||Listen|
|5/6/2015||Q115||$0.73||$0.72||$544.70 million||$543.30 million||View||Listen|
|2/5/2015||Q414||$0.81||$0.77||$600.20 million||$609.60 million||View||Listen|
|11/5/2014||Q314||$0.93||$1.12||$628.83 million||$638.80 million||View||Listen|
|8/6/2014||Q214||$1.28||$1.13||$709.03 million||$650.00 million||View||Listen|
|5/6/2014||Q114||$0.94||$1.05||$656.82 million||$671.10 million||View||Listen|
|3/3/2014||Q413||$1.99||$2.02||$1.07 billion||$1.06 billion||View||Listen|
|10/22/2013||Q313||$1.41||$1.80||$806.19 million||$927.00 million||View||Listen|
|8/1/2013||Q2 2013||$0.96||$1.22||$579.10 million||$682.90 million||View||Listen|
|5/2/2013||Q1 2013||$0.81||$0.90||$508.06 million||$550.10 million||View||Listen|
|2/6/2013||Q4 2012||$0.94||$0.97||$579.50 million||$588.20 million||View||Listen|
|10/31/2012||Q312||$0.77||$0.87||$480.72 million||$526.20 million||View||N/A|
Earnings Estimates for Nu Skin Enterprises (NYSE:NUS)
2017 EPS Consensus Estimate: $3.12
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Nu Skin Enterprises (NYSE:NUS)
|Most Recent Dividend:||9/13/2017|
|Dividend Growth:||5.80% (3 Year Average)|
|Payout Ratio:||48.81% (Trailing 12 Months of Earnings) |
44.44% (Based on This Year's Estimates)
42.11% (Based on Next Year's Estimates)
|Track Record:||16 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Nu Skin Enterprises (NYSE NUS)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Nu Skin Enterprises (NYSE:NUS)
Insider Ownership Percentage: 5.20%Insider Trades by Quarter for Nu Skin Enterprises (NYSE:NUS)
Institutional Ownership Percentage: 79.24%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/10/2017||Ryan S Napierski||President||Sell||6,933||$64.00||$443,712.00|| |
|9/7/2017||Daniel W Campbell||Director||Sell||4,607||$62.48||$287,845.36|| |
|8/10/2017||D Matthew Dorny||General Counsel||Sell||7,500||$60.88||$456,600.00|| |
|7/25/2017||Ryan S Napierski||President||Sell||8,000||$65.00||$520,000.00|| |
|7/5/2017||D Matthew Dorny||General Counsel||Sell||8,250||$62.92||$519,090.00|| |
|6/5/2017||D Matthew Dorny||General Counsel||Sell||8,000||$56.39||$451,120.00|| |
|5/11/2017||D Matthew Dorny||General Counsel||Sell||8,000||$58.32||$466,560.00|| |
|4/3/2017||D Matthew Dorny||General Counsel||Sell||8,000||$55.30||$442,400.00|| |
|3/6/2017||D Matthew Dorny||General Counsel||Sell||16,000||$50.00||$800,000.00|| |
|2/16/2017||Ryan S Napierski||Insider||Sell||8,400||$55.00||$462,000.00|| |
|1/6/2017||D Matthew Dorny||General Counsel||Sell||8,000||$50.00||$400,000.00|| |
|12/13/2016||D Matthew Dorny||General Counsel||Sell||20,000||$50.10||$1,002,000.00|| |
|10/26/2016||Steven Lund||Chairman||Sell||61,000||$61.55||$3,754,550.00|| |
|9/22/2016||Andrew D Lipman||Director||Sell||30,000||$64.13||$1,923,900.00|| |
|3/8/2016||Ritch N Wood||CFO||Buy||7,500||$33.32||$249,900.00|| |
|3/4/2016||Joseph Y Chang||Insider||Sell||20,000||$34.21||$684,200.00|| |
|8/18/2015||Scott E. Schwerdt||insider||Sell||18,750||$45.96||$861,750.00|| |
|7/6/2015||Daniel R Chard||Insider||Sell||17,500||$46.67||$816,725.00|| |
|11/26/2014||Ritch N Wood||CFO||Buy||2,500||$43.03||$107,575.00|| |
|11/14/2013||D Matthew Dorny||General Counsel||Sell||20,000||$112.50||$2,250,000.00|| |
|10/22/2013||Steven Lund||Chairman||Sell||50,000||$117.33||$5,866,500.00|| |
|9/6/2013||Steven Lund||Chairman||Sell||47,000||$86.07||$4,045,290.00|| |
|8/22/2013||Daniel Campbell||Director||Sell||8,203||$86.82||$712,184.46|| |
|8/21/2013||Patricia Negron||Director||Sell||5,000||$86.20||$431,000.00|| |
|8/6/2013||Steven Lund||Chairman||Sell||40,000||$87.33||$3,493,200.00|| |
Headline Trends for Nu Skin Enterprises (NYSE:NUS)
Latest Headlines for Nu Skin Enterprises (NYSE:NUS)
Loading headlines, please wait.
Nu Skin Enterprises (NUS) Chart for Saturday, October, 21, 2017